Regimen Reference Order

LYMP – brentuximab vedotin + DOXOrubicin + vinBLAStine + dacarbazine (brentuximab vedotin + AVD)

ARIA: LYMP – [brentuximab + AVD]

Planned Course: Every 28 days (Days 1 and 15) for 6 cycles
Indication for Use: Hodgkin Lymphoma

CVAD: At Provider's Discretion (VESICANT INVOLVED)

Proceed with treatment if:

Days 1 and 15

- ***Contact Hematologist if ANC less than 1 x 10^9/L OR Platelets less than 50 x 10^9/L***
  - ❖ ***DO NOT DELAY OR CANCEL THERAPY WITHOUT CONSULTING HEMATOLOGIST***

***Note:** Asymptomatic patients are not usually delayed for neutropenia regardless if ANC parameters are met. If the hematologist delays treatment, direction to be provided by the hematologist on management of neutropenia and length of delay*

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
allopurinol*	300 mg	Orally once daily for 10 days to begin 3 days prior to Cycle 1 and at provider's discretion for subsequent cycles **(Self-administered at home)** *Only patients at risk of tumor lysis syndrome will be prescribed allopurinol

Treatment Regimen – LYMP – brentuximab vedotin + AVD

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Days 1 and 15		
aprepitant	125 mg	Orally 1 hour pre-chemotherapy
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy
DOXOrubicin	25 mg/m^2	IV Push over 10 to 15 minutes
vinBLAStine	6 mg/m^2	IV in normal saline 25 mL over 5 to 10 minutes by gravity infusion
dacarbazine	375 mg/m^2	IV in D5W 500 mL over 2 hours *Concentration dependent drug: Pharmacy will adjust diluent volume to ensure drug stability*

cetirizine	10 mg	Orally 30 minutes prior to brentuximab vedotin
acetaminophen	650 mg	Orally 30 minutes prior to brentuximab vedotin
brentuximab vedotin	1.2 mg/kg; maximum dose 120 mg	IV in normal saline 100 mL over 30 minutes *Concentration dependent drug: Pharmacy will adjust diluent volume to ensure drug stability*
All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See LYMP DSG – Dose Banding document for more information		

In the event of an infusion-related hypersensitivity reaction, refer to the **'Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

All Cycles

- Assess patient for neuropathy prior to every cycle

Days 1 and 15

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid, glucose and albumin as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) prior to each dose of brentuximab vedotin and as clinically indicated
- No observation period is required after brentuximab vedotin administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Cardiac Monitoring

- Left Ventricular Ejection Fraction (LVEF) monitoring is recommended at baseline at physician's discretion and as clinically indicated

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
pegfilgrastim (brand name specific) *(See Filgrastim Clinical Guide)*	6 mg	Subcutaneous once on Days 2 and 16 **Alert: pegfilgrastim to be given as a single dose once after each Day of chemotherapy no sooner than 24 hours after chemotherapy*
aprepitant	80 mg	Orally once daily on Days 2, 3, 16 and 17
dexamethasone	8 mg	Orally once daily on Days 2, 3, 16 and 17
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
- brentuximab vedotin has potential for significant drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Cumulative DOXOrubicin dose should be calculated and should not exceed 450 mg/m^2
- brentuximab vedotin must be the last medication administered on Days 1 and 15
- brentuximab vedotin can cause peripheral neuropathy